Keytruda, the recently US approved drug shows early promise for some patients with advanced lung cancer though it is approved for advanced melanoma. The drug boosts the cancer-fighting potential and the body's immune system.
Keytruda (pembrolizumab) belongs to a new group of drugs that blocks a pathway called PD-1, which then frees up the immune system to attack cancer cells approved another PD-1 drug nivolumab (Opdivo) for treating some cases of advanced lung cancer.
Tumor Markers For Cancer Diagnosis and Prognosis
An ideal tumor marker for a cancer should be specific to that cancer and not generate false positive results.
Advertisement
The U.S. National Cancer Institute estimates that only about one-third of patients see any tumor shrinkage with standard chemotherapy, and even with treatment, people typically survive for a year.
The Merck-funded study involved 495 patients in the advanced stages of non-small-cell lung cancer, and infused Keytruda every two to three weeks. Dr. Edward Garon, an associate professor of medicine at the University of California, Los Angeles and his team analyzed their tumor samples to measure levels of a protein called PD-L1 and correlate with their likelihood of responding to the treatment.
The tumors for nearly 19% patients shrunk by 30% but among patients with PD-L1 activity, 45% responded to the drug. Although Keytruda is on the market, it is not specifically approved for lung cancer yet.
Source: Medindia
The tumors for nearly 19% patients shrunk by 30% but among patients with PD-L1 activity, 45% responded to the drug. Although Keytruda is on the market, it is not specifically approved for lung cancer yet.
Source: Medindia
Advertisement
 Lung BiopsyThe procedure by which tissue samples are obtained from the lung is known as lung biopsy. The biopsy tissues obtained from the lungs are examined by a pathologist. | Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
Safety and effectiveness of commonly used painkillers (analgesics) for short-term relief of low back pain remain uncertain.
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.